Pheast Therapeutics Highlights Preclinical Data of PHST001 at SITC 2024
Shots:
- Pheast Therapeutics highlighted new preclinical data of PHST001, an anti-CD24 antibody designed to block a key "don’t eat me" signal on cancer cells, promoting immune response, at SITC 2024
- The poster was entitled as, ‘PHST001, a humanized anti-CD24 antibody, induces phagocytosis of human tumor cells in vitro and tumor clearance in vivo’
- The preclinical data depicted that PHST001 attaches with CD24 and induces macrophage-driven phagocytosis, significantly reducing tumors in vivo and a favorable PK profile without immune-mediated toxicity among non-human primates in vitro. Pheast plans to start clinical trials in H1’25
Ref: Pheast Therapeutics | Image: Pheast Therapeutics
Related News:- Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.